Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

~ Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million ~ Agreement executed with Columbia University to develop novel oligonucleotide platform for the treatment of genetically driven cancers, including KRAS-driven cancers, and coronaviruses

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here